Cardiovascular Endocrinology and Metabolism

Part 1. Basic science and pathophysiology
1. Obesity and insulin resistance
2. Diabetes and macrovascular disease: epidemiology and cardiovascular risk assessment
3. Hypertension
4. Lipid metabolism: role in atherogenesis
5. Renal disease and cardiorenal interactions
6. NAFLD/NASH and cardiovascular risk
7. Heart failure
8. Prothrombosis: association with cardiometabolic disease
9. Inflammation, metabolism and cardiovascular disease
10. Classic endocrine disorders: association with vascular disease

Part 2. Clinical evaluation, lifestyle measures and therapeutic options
11. Non-pharmacological strategies in the prevention and management of cardiometabolic disease
12. Obesity: pharmacological approaches to prevention and management
13. Diabetes: evolution of multifactorial vascular risk reduction
14. Diabetes CVOTS: design, interpretation and future directions
15. Novel glucose-lowering drugs: a new era of cardioprotection and renoprotection
16: Hypertension: pharmacological and surgical management
17. PCSK-9 inhibitors and other novel lipid-modifying drugs
18. Recent therapeutic developments in heart failure
19. Antiplatelet agents
20. Progress in anticoagulant therapy
21. Invasive treatment of atherosclerotic cardiovascular disease: today and tomorrow
22. Cardiometabolic medicine in practice: role of cardiologists vs endocrinologists and the need for a new clinical specialty

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Diabetes
• Medicina cardiovascular

Active transport; Adiposity-based chronic disease; Apolipoprotein B; Atherosclerosis; Atherosclerotic cardiovascular disease; Atherosclerotic cardiovascular diseases; Body weight; Branched-chain amino acid oxidation; CVOT; Cardiometabolic disease; Cardiometabolic syndrome; Cardiomyopathy; Cardioprotection; Cardiovascular; Cardiovascular disease; Cardiovascular outcome trials; Cardiovascular risk; Cardiovascular risk assessment; Cardiovascular risk factors; Cardiovascular system; Coronary artery bypass grafting; Diabetes; Diabetes mellitus; Disease prevention; Endocrine disorders; Endocrine system; Endothelium; Epidemiology; Ezetimibe; Fatty acid oxidation; GLP-1 RAs; Glucose oxidation; Glycemic control; Glycolysis; HMG Co-A reductase inhibitor; Heart disease; Heart failure; Hemostasis; Hyperlipidemia; Hypertension; Inflammation; Insulin resistance; Ketone body oxidation; Kidney disease; LDL-cholesterol; Lithotripsy; Metabolic syndrome; Metabolism; Mortality; Multifactorial; Obesity; Obesity management; Peripheral arterial disease; Renal glucose; Renoprotection; Retinopathy; Revascularization; Risk factor control; SGLT-1; SGLT-2; SGLT2i; Smoking; Treatment; Type 2 diabetes